1. Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N,Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K,Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donorswith resolved hepatitis B virus infection. J Viral Hepat 29(11), 976-985
2. Sho T, Suda G, Yamamoto Y, Furuya K, Baba M, Ogawa K, Kubo A, Tokuchi Y, FuQ, Yang Z, Kimura M, Kitagataya T, Maehara O, Ohnishi S, Nakamura A, Yamada R,Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Suzuki K, Izumi T, Meguro T,Terashita K, Takagi T, Ito J, Kobayashi T, Miyagishima T, Sakamoto N.. Efficacyand Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet EligibilityCriteria of IMbrave150. Cancers (Basel) 14(16), :3938
3. Yoshida S, Suda G, Ohara M, Kimura M, Yang Z, Maehara O, Fu Q, Hosoda S,Akinori K, Tokuchi Y, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Overestimatedrenal function in patients with liver cirrhosis predicts poor prognosis.. Hepatol Res. 52(7), 603-613
4. Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, Kitagataya T,Shigesawa T, Shimazaki T, Kimura M, Suzuki K, Nakamura A, Ohara M, Kawagishi N,Izumi T, Nakai M, Sho T, Suda G, Natsuizaka M, Ono K, Murata K, Sugiyama M,Mizokami M, Sakamoto N. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.. Hepatol Res. 52(7):, :586-596
5. Nakamura A, Yamamoto K, Takeda R, Yamada R, Kubo A, Morikawa K, Ando S, Shimazaki T, Izumi T, Umemura M, Kitagataya T, Shigesawa T, Suzuki K, Kimura M,Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Ohnishi S, Sugiyama T, Takeda H, Sakamoto N. . The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. Hepatol Res 52(6):, 508-521.
6. Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R,Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N,Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Effect ofswitching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipidprofiles in patients with hepatitis B. PLoS One. 17(1), :e0261760
7. Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A,Tokuchi Y, Fu Q, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T,Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N.. Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival inPatients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 4(1):, 232
8. Fu Q, Ohnishi S, Suda G, Sakamoto N. Small-molecule inhibitor cocktail promotes the proliferation of pre-existing liver progenitor cells.. Stem Cell Reports 17, 1589-1603